Clinical observation of bevacizumab versus anlotinib respectively combined with chemotherapy drug in the treatment of EGFR-TKI acquired resistant advanced lung adenocarcinoma
- VernacularTitle:贝伐珠单抗与安罗替尼分别联合化疗药用于EGFR-TKI获得性耐药晚期肺腺癌的临床观察
- Author:
Yanyu QI
1
;
Tingting XIONG
2
;
Jun ZHANG
1
;
Han WANG
3
;
Congming ZHOU
1
;
Shasha JIANG
1
Author Information
1. Dept. of Oncology，the Third People’s Hospital of Chengdu，Chengdu 610404，China
2. Dept. of Clinical Pharmacy，Sichuan Provincial Maternity and Child Health Hospital/Sichuan Provincial Hospital for Women and Children/the Affiliated Women and Children’s Hospital of Chengdu Medical College，Chengdu 610031，China
3. Dept. of Cardiology，the Third People’s Hospital of Chengdu，Chengdu 610404，China
- Publication Type:Journal Article
- Keywords:
bevacizumab;
anlotinib;
epidermal growth factor receptor-tyrosine kinase inhibitors;
lung adenocarcinoma
- From:
China Pharmacy
2023;34(20):2525-2529
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To compare the short-term therapeutic effect and safety of bevacizumab versus anlotinib respectively combined with chemotherapy drug in the treatment of epidermal growth factor receptor tyrosine kinase inhibitors （EGFR-TKI） acquired resistant advanced lung adenocarcinoma. METHODS The information of 84 patients with EGFR-TKI acquired resistant advanced lung adenocarcinoma in the Third People’s Hospital of Chengdu was analyzed retrospectively during Jun. 2019-Oct. 2021. The patients were divided into chemotherapy group （32 cases）， anlotinib combined chemotherapy group （24 cases） and bevacizumab combined chemotherapy group （28 cases）. Patients in the chemotherapy group were given Pemetrexed disodium for injection and Carboplatin injection， and symptomatic treatment was given for adverse reactions. On the first day of chemotherapy， patients in the anlotinib combined chemotherapy group received Anlotinib hydrochloride capsules 10 mg orally， once a day， for 14 consecutive days and 7 days of discontinuation， based on the treatment of the chemotherapy group. Patients in the bevacizumab combined chemotherapy group were given Bevacizumab injection of 15 mg/kg intravenously 1 day before chemotherapy， based on the treatment of the chemotherapy group. Three groups of patients were treated for a total of four cycles， with one cycle every three weeks. The overall response rate （ORR）， disease control rate （DCR）， median progression-free survival （mPFS）， and the changes of serum tumor markers were compared among three groups before and after treatment； meanwhile， the occurrence of adverse drug reactions was recorded， and the 1-year survival rate was followed up. RESULTS After 4 treatment cycles， ORR and DCR of bevacizumab combined chemotherapy group and anlotinib combined chemotherapy group were higher than chemotherapy group （P＜0.05）； mPFS of the two groups were significantly longer than chemotherapy group， and DCR of anlotinib combined chemotherapy group was significantly higher than bevacizumab combined chemotherapy group （P＜0.05）. After 4 treatment cycles， the serum levels of tumor markers in three groups were significantly lower than before treatment， and both combined chemotherapy groups were significantly lower than chemotherapy group （P＜0.05）. There was no statistically significant difference in the incidence of adverse reactions such as nausea， vomiting， bone marrow suppression， and 1-year survival rate among the three groups of patients （P＞0.05）. CONCLUSIONS Bevacizumab and anlotinib combined with chemotherapy drug are effective and safe in the treatment of advanced lung adenocarcinoma with acquired EGFR-TKI resistance.
